MAP3K5 and myocardial infarction: Indeed, ASK1 inhibitors have been developed and passed into phase-III clinical trials.16,17 In the heart, ASK1 is activated in mouse models of pressure-overload,14 ischemia/reperfusion,18 myocardial infarction,14 and hypertension induced by Ang II (angiotensin II),19 all of which are associated with increased ROS.